Get the Stockscreener App
0.6003
0.38%
0.0023
After Hours:
.62
0.0197
+3.28%
Unicycive Therapeutics Inc stock is traded at $0.6003, with a volume of 184.04K.
It is up +0.38% in the last 24 hours and up +3.32% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$0.598
Open:
$0.598
24h Volume:
184.04K
Relative Volume:
0.19
Market Cap:
$73.02M
Revenue:
-
Net Income/Loss:
$-30.54M
P/E Ratio:
-0.3873
EPS:
-1.55
Net Cash Flow:
$-18.30M
1W Performance:
+13.24%
1M Performance:
+3.32%
6M Performance:
+31.96%
1Y Performance:
-48.03%
1-Day Range:
$0.5975
$0.6103
1-Week Range:
$0.503
$0.6282
52-Week Range:
$0.202
$1.289
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
0.6003 | 73.02M | 0 | -30.54M | -18.30M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
HC Wainwright Reiterates “Buy” Rating for Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
H.C. Wainwright maintains Unicycive Buy rating, $7.50 target By Investing.com - Investing.com Canada
Unicycive Therapeutics: Buy Rating on Imminent FDA Approval and Market Potential of Oxylanthanum Carbonate - TipRanks
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis - GlobeNewswire
Breakthrough: Unicycive's New Kidney Drug Cuts Pills in Half, 98% of Patients Report Easy Use - Stock Titan
Unicycive Therapeutics Inc Inc. (UNCY) Price Performance: A Technical Analysis Perspective - investchronicle.com
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R) - ACCESS Newswire
UNCY FY2025 EPS Lifted by Brookline Capital Management - Defense World
HC Wainwright Issues Pessimistic Estimate for UNCY Earnings - Defense World
Brookline Capital Management Weighs in on UNCY Q1 Earnings - Defense World
HC Wainwright Issues Positive Forecast for Unicycive Therapeutics (NASDAQ:UNCY) Stock Price - Defense World
Unicycive stock target raised to $7.50 by H.C. Wainwright - Investing.com Canada
Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS - MarketBeat
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Exclusive Look: Unicycive Unveils Latest Kidney Disease Breakthroughs at Major Healthcare Conference - Stock Titan
Noble Financial Sticks to Their Buy Rating for Unicycive Therapeutics (UNCY) - The Globe and Mail
Unicycive Therapeutics, Inc. SEC 10-K Report - TradingView
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
FDA to Review Unicycive's Kidney Disease Drug in June 2025: Key Financial Updates - Stock Titan
Unicycive Approaches Its First Approval, But In A Competitive Space - insights.citeline.com
Targeting Pressing Unmet Needs in Kidney Diseases with Unicycive Therapeutics CEO Dr. Shalabh Gupta - iHeart
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday - Defense World
Unicycive to Highlight Patient Reported Outcomes Data at - GlobeNewswire
Revolutionary Dialysis Treatment Cuts Pill Burden in Half: Key Clinical Data Coming - StockTitan
Unicycive Therapeutics Inc (NASDAQ:UNCY) stock: Is this a flash in the pan today? - US Post News
Unicycive Therapeutics Inc (NASDAQ: UNCY) Is One Of The Hottest Stocks Right Now. - Stocks Register
Unicycive reports potential kidney disease treatment advance By Investing.com - Investing.com Nigeria
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 - The Manila Times
Unicycive reports potential kidney disease treatment advance - Investing.com
Unicycive Therapeutics Announces the Publication of - GlobeNewswire
Groundbreaking Kidney Disease Treatment Shows 41% Better ResultsCan This Change Dialysis Patient Care? - StockTitan
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 51.6% in January - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Loses Momentum, Closing at 0.57 - The Dwinnex
Investing in Unicycive Therapeutics Inc [UNCY]: What You Must Know - Knox Daily
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Is Expected To Breakeven In The Near Future - Simply Wall St
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Short Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Rises By 25.4% - MarketBeat
Trading Day Review: Unicycive Therapeutics Inc (UNCY) Gains Momentum, Closing at 0.61 - The Dwinnex
Unicycive Therapeutics' (UNCY) Buy Rating Reiterated at HC Wainwright - MarketBeat
Unicycive highlights challenges in phosphate management - MSN
Unicycive Therapeutics Inc (UNCY) Has A Gold Mine On Its Hands - Stocks Register
Unicycive Therapeutics (NASDAQ:UNCY) Earns “Buy” Rating from HC Wainwright - Defense World
Unicycive Therapeutics Announces the Publication of Patient - GlobeNewswire
Unicycive highlights challenges in phosphate management By Investing.com - Investing.com Australia
Unicycive Therapeutics Publishes Review on Patient Perspectives in Phosphate Management for Chronic Kidney Disease - Nasdaq
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science - GlobeNewswire Inc.
Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation - Yahoo Finance
Analyzing Imunon (NASDAQ:IMNN) & Unicycive Therapeutics (NASDAQ:UNCY) - Defense World
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update - MarketBeat
Unicycive Therapeutics’ (UNCY) Buy Rating Reiterated at HC Wainwright - Defense World
Unicycive Therapeutics Receives Notice of Non-Compliance from Nasdaq - Defense World
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):